Evidence map›Paper›PMID 33335731›Full record

ArticleMolecular and clinical oncology2021

Malignant gastrointestinal neuroectodermal tumor with BRAF mutation and a history of malignant melanoma: A case report.

Toshinari Yagi, Shigenori Nagata, Takashi Yamamoto, Toru Wakamatsu, Yoshinori Imura, Hironari Tamiya, Hideaki Sabe, Katsunari Yamashita, Satoshi Takenaka

Open access · diamondAbstract read
In one paragraph

Article in Molecular and clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Toshinari YagiDepartment of Outpatient Chemotherapy, Osaka International Cancer Institute, Osaka 541-8567, Japan.
Shigenori NagataDepartment of Diagnostic Pathology and Cytology, Osaka International Cancer Institute, Osaka 541-8567, Japan.
Takashi YamamotoDepartment of Clinical Laboratory, Osaka International Cancer Institute, Osaka 541-8567, Japan.
Toru WakamatsuDepartment of Orthopedic Surgery, Osaka International Cancer Institute, Osaka 541-8567, Japan.
Yoshinori ImuraDepartment of Orthopedic Surgery, Osaka International Cancer Institute, Osaka 541-8567, Japan.
Hironari TamiyaDepartment of Orthopedic Surgery, Osaka International Cancer Institute, Osaka 541-8567, Japan.
Hideaki SabeDepartment of Orthopedic Surgery, Osaka International Cancer Institute, Osaka 541-8567, Japan.
Katsunari YamashitaDepartment of Orthopedic Surgery, Osaka International Cancer Institute, Osaka 541-8567, Japan.
Satoshi TakenakaDepartment of Orthopedic Surgery, Osaka International Cancer Institute, Osaka 541-8567, Japan.
Osaka Medical Center for Cancer and Cardiovascular Diseases · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malignant gastrointestinal neuroectodermal tumors (GNETs), also called clear-cell sarcoma-like tumors of the gastrointestinal tract, are rare and highly aggressive tumors originating in the gastrointestinal tract. These tumors are generally immunohistochemically positive for S-100 protein (S-100) and SRY-related HMG-box 10 (SOX10), and often contain EWSR1-ATF1 or EWSR1-CREB1. The histological features of GNETs overlap with those of clear-cell sarcoma of the tendons and aponeuroses. However, GNETs immunohistochemically lack melanocyte-specific markers and often demonstrate positivity for CD56, synaptophysin and neuron-specific enolase. The present case reports a woman with a history of desmoplastic malignant melanoma exhibiting a BRAF mutation, which later transformed into a GNET of the small intestine with both a BRAF mutation and two subtypes of EWSR1-ATF1 fusion genes. Tumor cells were revealed to be weakly immunoreactive or negative for S-100 and SOX10, lacked markers of melanocytic differentiation and were focally positive for CD56. Combination therapy with dabrafenib mesylate and trametinib dimethyl sulfoxide proved to be temporarily effective against this tumor. The present case is relatively unique as, to the best of our knowledge, there is no case of GNET with a history of melanoma. Furthermore, there is no report of GNET exhibiting both a BRAF mutation and an EWSR1-ATF1 fusion gene. Further accumulation of similar cases is necessary to elucidate the pathological significance of this GNET having a BRAF mutation.

Indexed as

BRAFclear cell sarcoma-like tumor of the gastrointestinal tractdabrafenib mesylateEWSR1-ATF1malignant gastrointestinal neuroectodermal tumormalignant melanomatrametinib dimethyl sulfoxide

Identifiers

PMID33335731
PMCPMC7739819
OpenAlexW3111916806

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.